The FDA granted orphan designation to GlaxoSmithKline Research & Development Limited’s treatment of autosomal dominant polycystic kidney disease, according to a post to the agency’s website.
Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on GSK:
- GSK Executes Share Buyback as Part of Capital Management Strategy
- GSK’s gepotidacin approved by U.K. MHRA
- GSK’s Promising Phase 3 Study on Multiple Myeloma Treatment: A Market Game Changer?
- GSK’s Promising Phase 3 Study on Relapsed SCLC: A Potential Game Changer
- Veeva highlights GSK Vault CRM go-live across Europe